Skip to main content

Table 1 The IC50 of SFK inhibitors PP1 and PP2 and BCR-Abl kinase/Src kinase inhibitor Dasatinib on a panel of B lymphoma cells of human and murine origin.

From: Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth

 

IC50

PP1(μM)

PP2 (μM)

dasatinib (nM)

Murine lymphoma

BKS-2

8.0

7.4

8.3

 

WEHI-231

4.6

2.8

17.5

 

CH31

6.1

3.6

-

 

CH12.Lx

2.5

2.8

7.3

Human lymphoma

SudHL-4

1.9

3.1

30

 

SudHL-6

6.6

5.2

2.9

 

OCI-Ly-3

19.5

12.6

1400

 

OCI-Ly-10

3.3

2.0

9.9

 

BJAB

4.6

3.4

-

  1. The IC50 was determined using the equation derived from a linear regression of the data.